Please assess the completion status of the following clinical trial:

Trial Title: Does Welchol (Colesevelam Hydrochloride) Improve Colonic Transit in Diarrhea-predominant Irritable Bowel Syndrome (D-IBS)?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with D-IBS~* Aged 18-65 years~* No abdominal surgery (except appendectomy or cholecystectomy as long as patients IBS-diarrhea symptoms preceded the cholecystectomy~Exclusion Criteria:~* Participants with known chronic liver disease or Aspartate aminotransferase (AST) or Alanine transaminase (ALT) \> 2.0 X upper limit of normal~* Hypertriglyceridemia and pancreatitis by history~* Diabetes or hypoglycemia~* Significant coagulation disorder~* History of bowel obstruction~* Serum triglycerides \>500 mg/dL~* History of vitamin A, D, E, or K deficiencies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Colesevelam (Type: EXPERIMENTAL): Participants received colesevelam 1.875 g twice daily
- Placebo (Type: PLACEBO_COMPARATOR): Participants received an inert capsule matching the study drug twice daily, as prepared by the Mayo Clinic research pharmacy

Based on this trial design, predict the completion outcome and termination type (if applicable).